Christopher Hite, EVP & Chairman, Partnering at Royalty Pharma plc (RPRX), sold 150,000 shares at $54.11 ($8.2M) on 2026-06-23, disclosed to the SEC on 2026-06-25.
Scheduled sale ($8.2M) by EVP & Chairman, Partnering under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $54.11 | 32,408 | $1.8M | 21.5% |
| 2 | $54.47 | 117,592 | $6.4M | 78.5% |
| Total | $54.40 avg | 150,000 | $8.2M | 100% |
| Filing → |
| RPRX | SELL | 2026-07-02 | $7.3M | — | Filing → |
| RPRX | BUY | 2020-06-23 | $2.0M | — | Filing → |